Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced on Monday that the Phase III Aranote trial demonstrated that Darolutamide combined with androgen deprivation therapy (ADT) significantly lowered the risk of radiological progression or death compared to a placebo with ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
The Aranote study revealed a statistically significant improvement in radiological progression-free survival compared to the placebo plus ADT group. Darolutamide plus ADT has now shown positive outcomes both with and without the inclusion of docetaxel, corroborated by data from two pivotal Phase III studies targeting mHSPC.
Additionally, a safety analysis reaffirmed Darolutamide's established tolerability profile.
Bayer intends to submit the Aranote trial data to global health authorities to endorse the extended use of Darolutamide in mHSPC treatment.
The Aranote trial, a randomized, double-blind, placebo-controlled Phase III study, is designed to evaluate the efficacy and safety of Darolutamide in combination with ADT for patients with mHSPC.
Darolutamide is an oral androgen receptor inhibitor featuring a unique chemical structure that binds to the androgen receptor with high affinity, thereby exhibiting strong antagonistic activity. This mechanism effectively inhibits receptor function and impedes the growth of prostate cancer cells.
